Global Human Vaccines

Human Vaccines Comprehensive Study by Type (Live-Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, Toxoid Vaccines), Distribution Channel (Hospital Pharmacies, Drugstores), Age Group (Pediatrics, Adolescents, Adults, Geriatrics) Players and Region - Global Market Outlook to 2026

Human Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Human Vaccines Market Overview:
Human vaccines prime the body's immune system to fight an incoming disease. Vaccines are proved to have better efficacy in comparison to other modes of drug administration. Rising awareness about vaccines and their crucial advantages has led to significant growth in the human vaccines market. The market is forecasted to grow in the future since vaccines pose lower risks of side effects and infections relatively.

Growth Drivers
  • Lower Risk of Side Effects Is Leading to Increased Demand
  • Government Initiatives Taken in Various Countries for Vaccines

Roadblocks
  • Vaccine Uptake Highly Skewed Towards High Mortality Diseases
  • High Cost of Human Vaccines, and Storage and Handling

Opportunities
  • Accelerate Uptake and Increasing Demand in Low-Income Countries
  • Rising Healthcare Access in Developing Nations

Challenges
  • Long and Complex Manufacturing Processes


Competitive Landscape:

Some of the key players profiled in the report are GlaxoSmithKline (United Kingdom), Merck (United States), Pfizer (United States), Sanofi (France ), Novavax (United States), Emergent BioSolutions (United States), CSL (Australia), Inovio Pharmaceuticals (United States), Bavarian Nordic (Denmark) and Mitsubishi Tanabe (Japan). Additionally, following companies can also be profiled that are part of our coverage like Astellas Pharma Inc. (Japan), AstraZeneca (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland), Gilead Sciences (United States), SELLAS Life Sciences Group, Inc. (United States), Serum Institute of India Pvt. Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Ltd. (Japan) and Teva Pharmaceutical Industries Ltd. (Israel). Analyst at AMA Research see United States Players to retain maximum share of Global Human Vaccines market by 2026. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Human Vaccines market. Considering Market by Age Group, the sub-segment i.e. Pediatrics will boost the Human Vaccines market.

Latest Market Insights:
In June 2018, Telethon Kids Institute in Australia has joined the Human Vaccines Project as its first international scientific hub, bringing significant health and scientific expertise in the areas of vaccines as well as working in pediatric and indigenous populations. The institute’s capacity will enhance the Project’s efforts toward better vaccines and immunotherapies, as well as work towards a universal flu vaccine.

In November 2019, FDA approved Fluzone® High-Dose Quadrivalent (Influenza Vaccine) introduced by Sanofi. This vaccine is intended for adults 65 years of age and older. This approval is the final step toward the company’s complete transition to quadrivalent influenza vaccines in the U.S. Fluzone High-Dose Quadrivalent will be made available for immunization efforts during the 2020-2021 influenza season.

The U.S. Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and ResearchExternal (CBER) is responsible for regulating vaccines in the United States. FDA can require a manufacturer to submit the results of their own tests for potency, safety, and purity for each vaccine lot. The Vaccine Adverse Event Reporting System (VAERS) is a national vaccine safety surveillance program co-sponsored by the Food and Drug Administration (FDA) and the CDC.

What Can be Explored with the Human Vaccines Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Human Vaccines Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Human Vaccines
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Human Vaccines market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Human Vaccines market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Human vaccines Manufacturer, Distributor and Supplier, Healthcare Industry, Government Agencies, Raw Material Supplier, End-User, Research Companies and Traders/Distributors/Suppliers.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Live-Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
  • Toxoid Vaccines
By Distribution Channel
  • Hospital Pharmacies
  • Drugstores

By Age Group
  • Pediatrics
  • Adolescents
  • Adults
  • Geriatrics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Lower Risk of Side Effects Is Leading to Increased Demand
      • 3.2.2. Government Initiatives Taken in Various Countries for Vaccines
    • 3.3. Market Challenges
      • 3.3.1. Long and Complex Manufacturing Processes
    • 3.4. Market Trends
      • 3.4.1. Researches and Trials of HIV-1 and Certain Types of Cancer Vaccines to Improve Immune Response
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Human Vaccines, by Type, Distribution Channel, Age Group and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Human Vaccines (Value)
      • 5.2.1. Global Human Vaccines by: Type (Value)
        • 5.2.1.1. Live-Attenuated Vaccines
        • 5.2.1.2. Inactivated Vaccines
        • 5.2.1.3. Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
        • 5.2.1.4. Toxoid Vaccines
      • 5.2.2. Global Human Vaccines by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Drugstores
      • 5.2.3. Global Human Vaccines by: Age Group (Value)
        • 5.2.3.1. Pediatrics
        • 5.2.3.2. Adolescents
        • 5.2.3.3. Adults
        • 5.2.3.4. Geriatrics
      • 5.2.4. Global Human Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Human Vaccines (Volume)
      • 5.3.1. Global Human Vaccines by: Type (Volume)
        • 5.3.1.1. Live-Attenuated Vaccines
        • 5.3.1.2. Inactivated Vaccines
        • 5.3.1.3. Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
        • 5.3.1.4. Toxoid Vaccines
      • 5.3.2. Global Human Vaccines by: Distribution Channel (Volume)
        • 5.3.2.1. Hospital Pharmacies
        • 5.3.2.2. Drugstores
      • 5.3.3. Global Human Vaccines by: Age Group (Volume)
        • 5.3.3.1. Pediatrics
        • 5.3.3.2. Adolescents
        • 5.3.3.3. Adults
        • 5.3.3.4. Geriatrics
      • 5.3.4. Global Human Vaccines Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Human Vaccines (Price)
      • 5.4.1. Global Human Vaccines by: Type (Price)
  • 6. Human Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France )
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novavax (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Emergent BioSolutions (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. CSL (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Inovio Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bavarian Nordic (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mitsubishi Tanabe (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Human Vaccines Sale, by Type, Distribution Channel, Age Group and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Human Vaccines (Value)
      • 7.2.1. Global Human Vaccines by: Type (Value)
        • 7.2.1.1. Live-Attenuated Vaccines
        • 7.2.1.2. Inactivated Vaccines
        • 7.2.1.3. Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
        • 7.2.1.4. Toxoid Vaccines
      • 7.2.2. Global Human Vaccines by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Drugstores
      • 7.2.3. Global Human Vaccines by: Age Group (Value)
        • 7.2.3.1. Pediatrics
        • 7.2.3.2. Adolescents
        • 7.2.3.3. Adults
        • 7.2.3.4. Geriatrics
      • 7.2.4. Global Human Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Human Vaccines (Volume)
      • 7.3.1. Global Human Vaccines by: Type (Volume)
        • 7.3.1.1. Live-Attenuated Vaccines
        • 7.3.1.2. Inactivated Vaccines
        • 7.3.1.3. Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
        • 7.3.1.4. Toxoid Vaccines
      • 7.3.2. Global Human Vaccines by: Distribution Channel (Volume)
        • 7.3.2.1. Hospital Pharmacies
        • 7.3.2.2. Drugstores
      • 7.3.3. Global Human Vaccines by: Age Group (Volume)
        • 7.3.3.1. Pediatrics
        • 7.3.3.2. Adolescents
        • 7.3.3.3. Adults
        • 7.3.3.4. Geriatrics
      • 7.3.4. Global Human Vaccines Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Human Vaccines (Price)
      • 7.4.1. Global Human Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Human Vaccines: by Type(USD Million)
  • Table 2. Human Vaccines Live-Attenuated Vaccines , by Region USD Million (2015-2020)
  • Table 3. Human Vaccines Inactivated Vaccines , by Region USD Million (2015-2020)
  • Table 4. Human Vaccines Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines , by Region USD Million (2015-2020)
  • Table 5. Human Vaccines Toxoid Vaccines , by Region USD Million (2015-2020)
  • Table 6. Human Vaccines: by Distribution Channel(USD Million)
  • Table 7. Human Vaccines Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Human Vaccines Drugstores , by Region USD Million (2015-2020)
  • Table 9. Human Vaccines: by Age Group(USD Million)
  • Table 10. Human Vaccines Pediatrics , by Region USD Million (2015-2020)
  • Table 11. Human Vaccines Adolescents , by Region USD Million (2015-2020)
  • Table 12. Human Vaccines Adults , by Region USD Million (2015-2020)
  • Table 13. Human Vaccines Geriatrics , by Region USD Million (2015-2020)
  • Table 14. South America Human Vaccines, by Country USD Million (2015-2020)
  • Table 15. South America Human Vaccines, by Type USD Million (2015-2020)
  • Table 16. South America Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 17. South America Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 18. Brazil Human Vaccines, by Type USD Million (2015-2020)
  • Table 19. Brazil Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 20. Brazil Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 21. Argentina Human Vaccines, by Type USD Million (2015-2020)
  • Table 22. Argentina Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 23. Argentina Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 24. Rest of South America Human Vaccines, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 26. Rest of South America Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 27. Asia Pacific Human Vaccines, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Human Vaccines, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 30. Asia Pacific Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 31. China Human Vaccines, by Type USD Million (2015-2020)
  • Table 32. China Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 33. China Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 34. Japan Human Vaccines, by Type USD Million (2015-2020)
  • Table 35. Japan Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 36. Japan Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 37. India Human Vaccines, by Type USD Million (2015-2020)
  • Table 38. India Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 39. India Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 40. South Korea Human Vaccines, by Type USD Million (2015-2020)
  • Table 41. South Korea Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 42. South Korea Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 43. Taiwan Human Vaccines, by Type USD Million (2015-2020)
  • Table 44. Taiwan Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 45. Taiwan Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 46. Australia Human Vaccines, by Type USD Million (2015-2020)
  • Table 47. Australia Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 48. Australia Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Human Vaccines, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 52. Europe Human Vaccines, by Country USD Million (2015-2020)
  • Table 53. Europe Human Vaccines, by Type USD Million (2015-2020)
  • Table 54. Europe Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 55. Europe Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 56. Germany Human Vaccines, by Type USD Million (2015-2020)
  • Table 57. Germany Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 58. Germany Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 59. France Human Vaccines, by Type USD Million (2015-2020)
  • Table 60. France Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 61. France Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 62. Italy Human Vaccines, by Type USD Million (2015-2020)
  • Table 63. Italy Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 64. Italy Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 65. United Kingdom Human Vaccines, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 67. United Kingdom Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 68. Netherlands Human Vaccines, by Type USD Million (2015-2020)
  • Table 69. Netherlands Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 70. Netherlands Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 71. Rest of Europe Human Vaccines, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 73. Rest of Europe Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 74. MEA Human Vaccines, by Country USD Million (2015-2020)
  • Table 75. MEA Human Vaccines, by Type USD Million (2015-2020)
  • Table 76. MEA Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 77. MEA Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 78. Middle East Human Vaccines, by Type USD Million (2015-2020)
  • Table 79. Middle East Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 80. Middle East Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 81. Africa Human Vaccines, by Type USD Million (2015-2020)
  • Table 82. Africa Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 83. Africa Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 84. North America Human Vaccines, by Country USD Million (2015-2020)
  • Table 85. North America Human Vaccines, by Type USD Million (2015-2020)
  • Table 86. North America Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 87. North America Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 88. United States Human Vaccines, by Type USD Million (2015-2020)
  • Table 89. United States Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 90. United States Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 91. Canada Human Vaccines, by Type USD Million (2015-2020)
  • Table 92. Canada Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 93. Canada Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 94. Mexico Human Vaccines, by Type USD Million (2015-2020)
  • Table 95. Mexico Human Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 96. Mexico Human Vaccines, by Age Group USD Million (2015-2020)
  • Table 97. Human Vaccines Sales: by Type(K Units)
  • Table 98. Human Vaccines Sales Live-Attenuated Vaccines , by Region K Units (2015-2020)
  • Table 99. Human Vaccines Sales Inactivated Vaccines , by Region K Units (2015-2020)
  • Table 100. Human Vaccines Sales Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines , by Region K Units (2015-2020)
  • Table 101. Human Vaccines Sales Toxoid Vaccines , by Region K Units (2015-2020)
  • Table 102. Human Vaccines Sales: by Distribution Channel(K Units)
  • Table 103. Human Vaccines Sales Hospital Pharmacies , by Region K Units (2015-2020)
  • Table 104. Human Vaccines Sales Drugstores , by Region K Units (2015-2020)
  • Table 105. Human Vaccines Sales: by Age Group(K Units)
  • Table 106. Human Vaccines Sales Pediatrics , by Region K Units (2015-2020)
  • Table 107. Human Vaccines Sales Adolescents , by Region K Units (2015-2020)
  • Table 108. Human Vaccines Sales Adults , by Region K Units (2015-2020)
  • Table 109. Human Vaccines Sales Geriatrics , by Region K Units (2015-2020)
  • Table 110. South America Human Vaccines Sales, by Country K Units (2015-2020)
  • Table 111. South America Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 112. South America Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 113. South America Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 114. Brazil Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 115. Brazil Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 116. Brazil Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 117. Argentina Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 118. Argentina Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 119. Argentina Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 120. Rest of South America Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 121. Rest of South America Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 122. Rest of South America Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 123. Asia Pacific Human Vaccines Sales, by Country K Units (2015-2020)
  • Table 124. Asia Pacific Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 125. Asia Pacific Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 126. Asia Pacific Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 127. China Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 128. China Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 129. China Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 130. Japan Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 131. Japan Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 132. Japan Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 133. India Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 134. India Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 135. India Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 136. South Korea Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 137. South Korea Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 138. South Korea Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 139. Taiwan Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 140. Taiwan Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 141. Taiwan Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 142. Australia Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 143. Australia Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 144. Australia Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 145. Rest of Asia-Pacific Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 146. Rest of Asia-Pacific Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 147. Rest of Asia-Pacific Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 148. Europe Human Vaccines Sales, by Country K Units (2015-2020)
  • Table 149. Europe Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 150. Europe Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 151. Europe Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 152. Germany Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 153. Germany Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 154. Germany Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 155. France Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 156. France Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 157. France Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 158. Italy Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 159. Italy Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 160. Italy Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 161. United Kingdom Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 162. United Kingdom Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 163. United Kingdom Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 164. Netherlands Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 165. Netherlands Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 166. Netherlands Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 167. Rest of Europe Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 168. Rest of Europe Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 169. Rest of Europe Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 170. MEA Human Vaccines Sales, by Country K Units (2015-2020)
  • Table 171. MEA Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 172. MEA Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 173. MEA Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 174. Middle East Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 175. Middle East Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 176. Middle East Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 177. Africa Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 178. Africa Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 179. Africa Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 180. North America Human Vaccines Sales, by Country K Units (2015-2020)
  • Table 181. North America Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 182. North America Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 183. North America Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 184. United States Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 185. United States Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 186. United States Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 187. Canada Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 188. Canada Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 189. Canada Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 190. Mexico Human Vaccines Sales, by Type K Units (2015-2020)
  • Table 191. Mexico Human Vaccines Sales, by Distribution Channel K Units (2015-2020)
  • Table 192. Mexico Human Vaccines Sales, by Age Group K Units (2015-2020)
  • Table 193. Human Vaccines: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Human Vaccines: by Type(USD Million)
  • Table 205. Human Vaccines Live-Attenuated Vaccines , by Region USD Million (2021-2026)
  • Table 206. Human Vaccines Inactivated Vaccines , by Region USD Million (2021-2026)
  • Table 207. Human Vaccines Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines , by Region USD Million (2021-2026)
  • Table 208. Human Vaccines Toxoid Vaccines , by Region USD Million (2021-2026)
  • Table 209. Human Vaccines: by Distribution Channel(USD Million)
  • Table 210. Human Vaccines Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 211. Human Vaccines Drugstores , by Region USD Million (2021-2026)
  • Table 212. Human Vaccines: by Age Group(USD Million)
  • Table 213. Human Vaccines Pediatrics , by Region USD Million (2021-2026)
  • Table 214. Human Vaccines Adolescents , by Region USD Million (2021-2026)
  • Table 215. Human Vaccines Adults , by Region USD Million (2021-2026)
  • Table 216. Human Vaccines Geriatrics , by Region USD Million (2021-2026)
  • Table 217. South America Human Vaccines, by Country USD Million (2021-2026)
  • Table 218. South America Human Vaccines, by Type USD Million (2021-2026)
  • Table 219. South America Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 220. South America Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 221. Brazil Human Vaccines, by Type USD Million (2021-2026)
  • Table 222. Brazil Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 223. Brazil Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 224. Argentina Human Vaccines, by Type USD Million (2021-2026)
  • Table 225. Argentina Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 226. Argentina Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 227. Rest of South America Human Vaccines, by Type USD Million (2021-2026)
  • Table 228. Rest of South America Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 229. Rest of South America Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 230. Asia Pacific Human Vaccines, by Country USD Million (2021-2026)
  • Table 231. Asia Pacific Human Vaccines, by Type USD Million (2021-2026)
  • Table 232. Asia Pacific Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 233. Asia Pacific Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 234. China Human Vaccines, by Type USD Million (2021-2026)
  • Table 235. China Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 236. China Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 237. Japan Human Vaccines, by Type USD Million (2021-2026)
  • Table 238. Japan Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 239. Japan Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 240. India Human Vaccines, by Type USD Million (2021-2026)
  • Table 241. India Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 242. India Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 243. South Korea Human Vaccines, by Type USD Million (2021-2026)
  • Table 244. South Korea Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 245. South Korea Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 246. Taiwan Human Vaccines, by Type USD Million (2021-2026)
  • Table 247. Taiwan Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 248. Taiwan Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 249. Australia Human Vaccines, by Type USD Million (2021-2026)
  • Table 250. Australia Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 251. Australia Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 252. Rest of Asia-Pacific Human Vaccines, by Type USD Million (2021-2026)
  • Table 253. Rest of Asia-Pacific Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 254. Rest of Asia-Pacific Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 255. Europe Human Vaccines, by Country USD Million (2021-2026)
  • Table 256. Europe Human Vaccines, by Type USD Million (2021-2026)
  • Table 257. Europe Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 258. Europe Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 259. Germany Human Vaccines, by Type USD Million (2021-2026)
  • Table 260. Germany Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 261. Germany Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 262. France Human Vaccines, by Type USD Million (2021-2026)
  • Table 263. France Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 264. France Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 265. Italy Human Vaccines, by Type USD Million (2021-2026)
  • Table 266. Italy Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 267. Italy Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 268. United Kingdom Human Vaccines, by Type USD Million (2021-2026)
  • Table 269. United Kingdom Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 270. United Kingdom Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 271. Netherlands Human Vaccines, by Type USD Million (2021-2026)
  • Table 272. Netherlands Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 273. Netherlands Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 274. Rest of Europe Human Vaccines, by Type USD Million (2021-2026)
  • Table 275. Rest of Europe Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 276. Rest of Europe Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 277. MEA Human Vaccines, by Country USD Million (2021-2026)
  • Table 278. MEA Human Vaccines, by Type USD Million (2021-2026)
  • Table 279. MEA Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 280. MEA Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 281. Middle East Human Vaccines, by Type USD Million (2021-2026)
  • Table 282. Middle East Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 283. Middle East Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 284. Africa Human Vaccines, by Type USD Million (2021-2026)
  • Table 285. Africa Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 286. Africa Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 287. North America Human Vaccines, by Country USD Million (2021-2026)
  • Table 288. North America Human Vaccines, by Type USD Million (2021-2026)
  • Table 289. North America Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 290. North America Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 291. United States Human Vaccines, by Type USD Million (2021-2026)
  • Table 292. United States Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 293. United States Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 294. Canada Human Vaccines, by Type USD Million (2021-2026)
  • Table 295. Canada Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 296. Canada Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 297. Mexico Human Vaccines, by Type USD Million (2021-2026)
  • Table 298. Mexico Human Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 299. Mexico Human Vaccines, by Age Group USD Million (2021-2026)
  • Table 300. Human Vaccines Sales: by Type(K Units)
  • Table 301. Human Vaccines Sales Live-Attenuated Vaccines , by Region K Units (2021-2026)
  • Table 302. Human Vaccines Sales Inactivated Vaccines , by Region K Units (2021-2026)
  • Table 303. Human Vaccines Sales Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines , by Region K Units (2021-2026)
  • Table 304. Human Vaccines Sales Toxoid Vaccines , by Region K Units (2021-2026)
  • Table 305. Human Vaccines Sales: by Distribution Channel(K Units)
  • Table 306. Human Vaccines Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 307. Human Vaccines Sales Drugstores , by Region K Units (2021-2026)
  • Table 308. Human Vaccines Sales: by Age Group(K Units)
  • Table 309. Human Vaccines Sales Pediatrics , by Region K Units (2021-2026)
  • Table 310. Human Vaccines Sales Adolescents , by Region K Units (2021-2026)
  • Table 311. Human Vaccines Sales Adults , by Region K Units (2021-2026)
  • Table 312. Human Vaccines Sales Geriatrics , by Region K Units (2021-2026)
  • Table 313. South America Human Vaccines Sales, by Country K Units (2021-2026)
  • Table 314. South America Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 315. South America Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 316. South America Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 317. Brazil Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 318. Brazil Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 319. Brazil Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 320. Argentina Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 321. Argentina Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 322. Argentina Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 323. Rest of South America Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 324. Rest of South America Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 325. Rest of South America Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 326. Asia Pacific Human Vaccines Sales, by Country K Units (2021-2026)
  • Table 327. Asia Pacific Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 328. Asia Pacific Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 329. Asia Pacific Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 330. China Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 331. China Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 332. China Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 333. Japan Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 334. Japan Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 335. Japan Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 336. India Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 337. India Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 338. India Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 339. South Korea Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 340. South Korea Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 341. South Korea Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 342. Taiwan Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 343. Taiwan Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 344. Taiwan Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 345. Australia Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 346. Australia Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 347. Australia Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 348. Rest of Asia-Pacific Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 349. Rest of Asia-Pacific Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 350. Rest of Asia-Pacific Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 351. Europe Human Vaccines Sales, by Country K Units (2021-2026)
  • Table 352. Europe Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 353. Europe Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 354. Europe Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 355. Germany Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 356. Germany Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 357. Germany Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 358. France Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 359. France Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 360. France Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 361. Italy Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 362. Italy Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 363. Italy Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 364. United Kingdom Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 365. United Kingdom Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 366. United Kingdom Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 367. Netherlands Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 368. Netherlands Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 369. Netherlands Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 370. Rest of Europe Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 371. Rest of Europe Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 372. Rest of Europe Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 373. MEA Human Vaccines Sales, by Country K Units (2021-2026)
  • Table 374. MEA Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 375. MEA Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 376. MEA Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 377. Middle East Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 378. Middle East Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 379. Middle East Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 380. Africa Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 381. Africa Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 382. Africa Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 383. North America Human Vaccines Sales, by Country K Units (2021-2026)
  • Table 384. North America Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 385. North America Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 386. North America Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 387. United States Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 388. United States Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 389. United States Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 390. Canada Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 391. Canada Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 392. Canada Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 393. Mexico Human Vaccines Sales, by Type K Units (2021-2026)
  • Table 394. Mexico Human Vaccines Sales, by Distribution Channel K Units (2021-2026)
  • Table 395. Mexico Human Vaccines Sales, by Age Group K Units (2021-2026)
  • Table 396. Human Vaccines: by Type(USD/Units)
  • Table 397. Research Programs/Design for This Report
  • Table 398. Key Data Information from Secondary Sources
  • Table 399. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Human Vaccines: by Type USD Million (2015-2020)
  • Figure 5. Global Human Vaccines: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Human Vaccines: by Age Group USD Million (2015-2020)
  • Figure 7. South America Human Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Human Vaccines Share (%), by Country
  • Figure 9. Europe Human Vaccines Share (%), by Country
  • Figure 10. MEA Human Vaccines Share (%), by Country
  • Figure 11. North America Human Vaccines Share (%), by Country
  • Figure 12. Global Human Vaccines: by Type K Units (2015-2020)
  • Figure 13. Global Human Vaccines: by Distribution Channel K Units (2015-2020)
  • Figure 14. Global Human Vaccines: by Age Group K Units (2015-2020)
  • Figure 15. South America Human Vaccines Share (%), by Country
  • Figure 16. Asia Pacific Human Vaccines Share (%), by Country
  • Figure 17. Europe Human Vaccines Share (%), by Country
  • Figure 18. MEA Human Vaccines Share (%), by Country
  • Figure 19. North America Human Vaccines Share (%), by Country
  • Figure 20. Global Human Vaccines: by Type USD/Units (2015-2020)
  • Figure 21. Global Human Vaccines share by Players 2020 (%)
  • Figure 22. Global Human Vaccines share by Players (Top 3) 2020(%)
  • Figure 23. Global Human Vaccines share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck (United States) Revenue: by Geography 2020
  • Figure 29. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer (United States) Revenue: by Geography 2020
  • Figure 31. Sanofi (France ) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi (France ) Revenue: by Geography 2020
  • Figure 33. Novavax (United States) Revenue, Net Income and Gross profit
  • Figure 34. Novavax (United States) Revenue: by Geography 2020
  • Figure 35. Emergent BioSolutions (United States) Revenue, Net Income and Gross profit
  • Figure 36. Emergent BioSolutions (United States) Revenue: by Geography 2020
  • Figure 37. CSL (Australia) Revenue, Net Income and Gross profit
  • Figure 38. CSL (Australia) Revenue: by Geography 2020
  • Figure 39. Inovio Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 40. Inovio Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 41. Bavarian Nordic (Denmark) Revenue, Net Income and Gross profit
  • Figure 42. Bavarian Nordic (Denmark) Revenue: by Geography 2020
  • Figure 43. Mitsubishi Tanabe (Japan) Revenue, Net Income and Gross profit
  • Figure 44. Mitsubishi Tanabe (Japan) Revenue: by Geography 2020
  • Figure 45. Global Human Vaccines: by Type USD Million (2021-2026)
  • Figure 46. Global Human Vaccines: by Distribution Channel USD Million (2021-2026)
  • Figure 47. Global Human Vaccines: by Age Group USD Million (2021-2026)
  • Figure 48. South America Human Vaccines Share (%), by Country
  • Figure 49. Asia Pacific Human Vaccines Share (%), by Country
  • Figure 50. Europe Human Vaccines Share (%), by Country
  • Figure 51. MEA Human Vaccines Share (%), by Country
  • Figure 52. North America Human Vaccines Share (%), by Country
  • Figure 53. Global Human Vaccines: by Type K Units (2021-2026)
  • Figure 54. Global Human Vaccines: by Distribution Channel K Units (2021-2026)
  • Figure 55. Global Human Vaccines: by Age Group K Units (2021-2026)
  • Figure 56. South America Human Vaccines Share (%), by Country
  • Figure 57. Asia Pacific Human Vaccines Share (%), by Country
  • Figure 58. Europe Human Vaccines Share (%), by Country
  • Figure 59. MEA Human Vaccines Share (%), by Country
  • Figure 60. North America Human Vaccines Share (%), by Country
  • Figure 61. Global Human Vaccines: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Merck (United States)
  • Pfizer (United States)
  • Sanofi (France )
  • Novavax (United States)
  • Emergent BioSolutions (United States)
  • CSL (Australia)
  • Inovio Pharmaceuticals (United States)
  • Bavarian Nordic (Denmark)
  • Mitsubishi Tanabe (Japan)
Additional players considered in the study are as follows:
Astellas Pharma Inc. (Japan) , AstraZeneca (United Kingdom) , F. Hoffmann-La Roche Ltd. (Switzerland) , Gilead Sciences (United States) , SELLAS Life Sciences Group, Inc. (United States) , Serum Institute of India Pvt. Ltd. (India) , Sun Pharmaceutical Industries Ltd. (India) , Takeda Pharmaceutical Company Ltd. (Japan) , Teva Pharmaceutical Industries Ltd. (Israel)
Select User Access Type

Key Highlights of Report


Oct 2021 221 Pages 72 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Human Vaccines Quantitative research analysis
Global Human Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Human Vaccines market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Human Vaccines market are GlaxoSmithKline (United Kingdom), Merck (United States), Pfizer (United States), Sanofi (France ), Novavax (United States), Emergent BioSolutions (United States), CSL (Australia), Inovio Pharmaceuticals (United States), Bavarian Nordic (Denmark) and Mitsubishi Tanabe (Japan), to name a few.
"Researches and Trials of HIV-1 and Certain Types of Cancer Vaccines to Improve Immune Response" is seen as one of major influencing trends for Human Vaccines Market during projected period 2020-2026.

Know More About Global Human Vaccines Report?

Have a Query? Click Here

Other Related Reports

Thin Film Drug Comprehensive Study by Type (Transdermal Film, Oral Thin Film), Application (Hospitals, Clinics, Others), Indication Type (Schizophrenia, Migraine, Opioid Dependence, Nausea & Vomiting...
$ 3750
Infusion Pharmacy Management Comprehensive Study by Type (Antibiotics, Antimicrobial, Pain Management, Enteral Nutrition, Others), Application (Hospital & Clinic, Ambulatory Surgical Centers, Home Ca...
$ 3350
Active Pharma Ingredient Comprehensive Study by Type (Innovative Active Pharmaceutical Ingredients, Generic Active Pharmaceutical Ingredients), Application (Oncology, Cardiovascular Disease, Diabetes...
$ 3750
Kinase Inhibitors Comprehensive Study by Type (Tyrosin Kinase Inhibitors (TKI), Receptor Tyrosine Kinase Inhibitors, Non-Receptor Tyrosine Kinase Inhibitors, Mulikinase Inhibitors, Threonine Kinase I...
$ 3750
Eye Care Products Comprehensive Study by Type (Artificial Tear Drops, Ointments or Emollients, Eye Washes, Hyperosomotics, Eyelid Scrubs, Decongestants, Antihistamines), Form (Cream, Solution, Other...
$ 3450
Calcitriol Comprehensive Study by Application (Osteoporosis, Renal Osteodystrophy, Others), Distribution Channel (Offline, Online), Form (Calcitriol Capsule, Calcitriol Solution), Disease Indication ...
$ 3450